Agora Labs raises €4.3M for hospital data research network
Fifty hospitals, one network, and no record leaves the building. P101 leads a €4.3 million round in the Rome company betting that Europe's privacy rules are the product.
Also see more funding coverage: /funding/
Founded 2022 · Rome, Italy
Agora Labs has raised €4.3 million to make hospital clinical data usable for medical research, in a round led by Italian investor P101 with Infinite Five, the Mussetto family holding company, joining.
The round was announced on October 27, 2026. P101 invested through its Programme 103 vehicles, which are backed by the EU InvestEU Fund and CDP Venture Capital. The announcement carried no stage label, so the round goes into our records as equity with no letter attached.
Get the Weekly brief
The week’s rounds, last calls and events, every Monday.
Agora Labs named four uses for the money: taking its network of healthcare facilities from 50 to 100, strengthening its position in Europe and the United States, entering the Middle East and India, and hiring around 20 technical and commercial people.
“Agora Labs has developed a solution that is unique in Europe,” said Stefano Guidotti, partner at P101, in the announcement.
Fifty hospitals, and the data never leaves any of them
Agora Labs was founded in Rome by Davide Zaccagnini, a vascular surgeon and biomedical computer scientist trained at MIT, and Fabio Giulietto, an engineer with an MBA from Imperial College London. The company came out of a European research project started after GDPR took effect in 2018, and commercial operations began in 2023. Our startup record puts the team at 19 people, working across Rome and Collevecchio.
The architecture is the pitch. Each hospital hosts an on-premises node running on Nvidia GPUs. Language models sitting on that node structure clinical records that were written for patient care and never for research, irreversible anonymization is applied on site, and federated AI lets research centers and pharma companies run multicentre studies across the whole network. “The data never leaves the hospital,” Zaccagnini says. Fifty facilities are connected today, and the round is meant to double that.
We have spent most of a decade treating European health privacy rules as the reason nothing ships here. The good news is that those same rules handed European builders a design problem their American competitors never had to solve, and so mostly have not solved. A company that can run a multicentre study across fifty hospitals without one record crossing a hospital firewall is selling that constraint, in Boston and in Riyadh, as the product.
A $10.8 billion market, and European rules that land in 2029
Who is going to carry European hospitals through March 2029?
The segment Agora Labs sells into is real-world evidence: the business of turning routine clinical records into something a regulator or a pharma company will accept as proof. It was worth $4.74 billion in 2024 and is forecast to reach $10.83 billion by 2030, a 14.8% compound annual growth rate across 2025 to 2030 (MarketsandMarkets, August 2025).
Sitting underneath that number is a date most European founders have not circled yet. The European Health Data Space Regulation (EU) 2025/327 entered into force on March 26, 2025, and its rules on the secondary use of health data start to apply in March 2029, with genomic and other remaining categories following in March 2031 (European Commission). Hospitals across the Union will be obliged to make data available for research under a common framework, and they will need infrastructure to do it with. Four and a half years is roughly the time it takes to build that infrastructure and win fifty more hospitals.
For scale, our own funding records put this round at the upper end of early European clinical-AI cheques. Cori Clinical raised a €3.55 million seed led by Breega in October 2026 for clinical trial design software, and Okeiro raised a €10 million Series A led by Red River West in April 2025. Yesterday also brought Atlas Bio’s €12.5 million for simulating drug trials, which is the same thesis approached from the modelling end.
What an Italian health-data round signals
Three things stand out, and none of them is the amount.
The first is where this was built. Italy is not where the European health AI map usually puts its pins, and P101 led from inside the country with family capital next to it and InvestEU underneath it. That stack, a domestic VC plus a family holding plus a public backstop, is how a lot of southern European deep tech is now getting to market, and it is worth watching whether it carries the company to a Series A that a larger European fund will price.
The second is the shape of the moat. Infrastructure that lives inside fifty hospitals is slow to build and slow to displace. Every node installed is a switching cost, which is the opposite of how most AI companies are currently being valued.
The third is the regulatory clock. Companies selling compliance infrastructure ahead of a European deadline have been quietly good businesses, and we saw the same pattern this month with Scarlet’s Series B for certifying AI medical devices. The buyers know the date is coming, and buying is faster than building.
Imagine if the next five years of European health AI are decided by who holds the hospital relationships in 2029, with the best model weights a distant second. On that reading, fifty on-premises nodes in Italian hospitals is a better asset than it looks at €4.3 million. Keep an eye on the European rounds going into clinical data infrastructure between now and March 2029. That is where the next quiet compounding is happening. Let’s build it!
